13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting AURKA, AURKB and AURKC could enhance the efficacy of T790M-mutant EGFR inhibitors against EGFR-mutant NSCLC. Screening of 94 compounds against cancer pathway...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
07:00 , Mar 31, 2016 |  BC Innovations  |  Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AZD2811: Phase I started

AstraZeneca began an open-label, U.S. Phase I trial to evaluate AZD2811 in about 77 patients. A dose-escalation part will determine the dose for the dose-expansion part, which will evaluate AZD2811 alone and with irinotecan. Dosing...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Bind Therapeutics, AstraZeneca preclinical data

In mouse xenograft models of small cell lung cancer (SCLC) and diffuse large B cell lymphoma (DLBCL), AZD2811 inhibited tumor growth and led to tumor regression. Data were presented at the American Association for Cancer...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

GSK1070916: Phase I data

Cancer Research UK (London, U.K.) said a dose-escalation, U.K. Phase I trial in 36 patients with advanced solid tumors showed that GSK1070916 was well tolerated and met undisclosed pre-determined success criteria. Based on the results,...
07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Aurora kinase A (AURKA; Aurora-A); AURKB (Aurora-B) In vitro and mouse studies suggest furanopyrimidine-based dual AURKA and AURKB inhibitors could help treat cancer....
08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Aurora kinase B (AURKB; aurora-B) In vitro and mouse studies identified an AURKB-specific inhibitor that could help treat cancer. In a ligand-docking screen, a...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Small cell lung cancer (SCLC) Aurora kinase B (AURKB; aurora-B); c-Myc (MYC) A cell screening study suggests aurora-B inhibitors could help treat SCLCs with MYC...